Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Income from Continuing Operations (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Income from Continuing Operations data on record, last reported at 24570541.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 95.68% year-over-year to 24570541.0; the TTM value through Sep 2025 reached 81760998.0, down 139.21%, while the annual FY2024 figure was 40361852.0, 80.6% down from the prior year.
  • Income from Continuing Operations reached 24570541.0 in Q3 2025 per CAPR's latest filing, up from 25925782.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 829093.0 in Q4 2023 and bottomed at 25925782.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 9869345.74, with a median of 7366579.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 89.21% in 2023, then plummeted 745.66% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 6363658.0 in 2021, then dropped by 20.79% to 7686646.0 in 2022, then surged by 89.21% to 829093.0 in 2023, then tumbled by 745.66% to 7011269.0 in 2024, then tumbled by 250.44% to 24570541.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 24570541.0 in Q3 2025, 25925782.0 in Q2 2025, and 24253406.0 in Q1 2025.